Moderna's shares surged 177% on August 19 following positive late-stage trial results for its experimental melanoma vaccine, developed in partnership with Merck.
However, Rothschild analyst Simon Baker expressed concerns that the market's reaction to the news was overly optimistic, suggesting that the stock's current valuation does not align with the limited data available on the vaccine's effectiveness against other cancer types. Following the downgrade, Moderna's stock has lost momentum, closing 14% below its peak from the August announcement.
While the broader analyst consensus remains more favorable, with two-thirds of analysts holding a neutral rating, Rothschild's position highlights a potential disconnect between market sentiment and the underlying fundamentals of the company. Shares have increased 411% year to date, but the downgrade has led to a nearly 2% decline in premarket trading, indicating investor caution moving forward